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Introduction: Lung cancer is one of the most common cancers with 
high mortality rate because of the late diagnosis. The present study 
aimed to quantitatively measure the C-X-C Motif Chemokine Ligand 5 
(CXCL5) gene expression level in tissue samples of lung cancer patients 
to investigate its value as a biomarker during lung cancer diagnosis and 
screening. 
Materials and Methods: Tissue samples were collected from 30 
patients. Total RNA was extracted from tumor and normal tissues of 
patients. The rate of CXCL5 gene expression was initially measured in 
A549 cell line and next, the expression level of this gene in tumor tissue 
samples of patients suffering from Non-Small Cell Lung Cancer was 
compared to the normal lung tissue of the same patients. 
Results: The results demonstrated significant increase of CXCL5 gene 
expression in cancer samples compared to normal tissues of the same 
samples. The increase was 5.8 fold for cancerous tissues in comparison 
with normal tissues (P=0.03). There was no difference between the 
tumor type (adenocarcinoma, squamous cell carcinoma) and average 
CXCL5 gene expression rate (P=0.09). In cancerous samples, the 
expression level of CXCL5 was higher in men compared with those of 
women (P=0.04). There was no relationship between the change of gene 
expression and the age of the patients (p=0.08). 
Conclusion: Based on the results, it can be concluded that the 
quantitative expression level of CXCL5 in lung cancer patients could be 
used as a biomarker to screen lung cancer samples, regardless of age of 
patients and tumor type. However, it can discriminate the stage of tumor.  
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     Lung cancer is regarded as the most 
common cancer worldwide. Statistics shows 
that the mortality rate of breast, prostate, 
and intestinal cancers altogether are less 
than the mortality of lung cancer [1]. More 
than 90% of lung cancer cases are issued by 
changes in lung basal epithelial cells and 
lung covering layer [2]. Lung epithelial 
cancers have four primary cell types, 
including small cell lung cancer (SCLC) 
and another group called non-small cell 
lung cancer (NSCLC), consisting of 
adenocarcinoma, squamous cell carcinoma 
(SCC) and large cell carcinoma [3]. 
One of the genes which expresses changes 
during the progression of lung cancer is 
CXCL5 (C-X-C Motif Chemokine Ligand 5 
fo neutrophil-activating epithelial peptide). 
It belongs to CXC-type chemokine family, 
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encoding small secretory proteins. The 
product of CXCL5 acts as an angiogenic 
chemokine which is considered as an 
inflammatory mediator and a potent 
absorber of neutrophils. There are some 
evidence about the role of CXCL in 
carcinogenesis and cancer progression [4]; 
for instance, the increase of CXCL5 
expression is observed in colorectal [5], 
prostate [6], endometrial [7], squamous cell 
and pancreatic cancers [8]. The expression 
is associated with advanced stages of tumor, 
local invasion and metastasis. These studies 
revealed that CXCL5 directly stimulates 
cancer cell proliferation. Besides, CXCL5 
directly causes endothelial cell proliferation 
and invasion in vitro, and also increases 
tumor angiogenesis in non-small cell lung 
carcinoma and pancreatic cancer [9]. 
CXCL5 gene is also called epithelial cell-
derived neutrophil-activating peptide ENA-
78 and is expressed by epithelial cells after 
stimulation by pro-inflammatory cytokines 
such as IL-1β and TNFα, which in turn, 
results in the absorption of 
polymorphonuclear neutrophils (PMN) 
[10]. On the other hand, the combination of 
HB-EGF (EGF-like growth factor binding 
to heparin) and mucosal neutrophils 
(activating peptide-78) makes a strong 
synergistic effect on cancer proliferation, 
epithelial-mesenchymal transition, 
migration and invasion. CXCL5 not only 
stimulates the classic pathway of EGFR and 
the signaling pathway AKT and ERK/ 
RSK1/ 2, but also increases heat shock 
protein phosphorylation (HSP27) [6].  
 CXCL5 is produced by different kinds of 
cells such as monocytes, neutrophilic 
dendritic cells, fibroblasts and mucosal 
cells. These cells involve in regulating the 
biological processes of cancer, including the 
induction of tumor angiogenesis by 
proliferation, endothelial cell invasion, 
mobility, invasion and tumor metastasis. 
Recent studies have indicated that CXCL5 
neutralization by antibody has a significant 
role in the incidence of cancer progression 
[11]. Some studies have suggested that 
CXCL5 is also released through stimulated 
endothelial cells in the lung and other 
human tissues and can cause the creation of 
pro-adhesive activity of neutrophils along 
with IL-8 [12]. 
Some researchers used the assessment of 
CXCL5 chemokine level as a biomarker for 
the diagnosis of prostate cancer. They stated 
that alteration of the gene expression was 
one of the primary causes of the prostate 
cancer initiation and by increasing its 
expression, the prognosis of the disease 
would get worse [13]. In another research 
assessing the expression level of chemokine 
showed to be a good predictor for cortical 
cancer prognosis [5]. Through using ELISA 
and the immunohistochemistry methods, it 
was shown that the expression level of this 
chemokine in tumor tissues was 
significantly higher than normal tissues. 
Therefore, it is applied as a biomarker to 
predict the diseases and determine the 
patient’s prognosis [14]. 
The possibility of using CXCL5 level 
assessment in the early diagnosis of lung 
cancer was proposed by Kowalczuk et al. 
They compared the expression of 18 
different genes in normal and cancerous 
tissues. The results demonstrated that a 
significant difference existed between the 
normal and cancerous tissues for CXCL5  
 gene expression [15].  
Since lung cancer is one of the major causes 
of global death and its 5-year survival rate 
is lower than other cancers [1], it is 
necessary to develop methods and tools 
leading to the early diagnosis of the disease 
and hence, the mortality reduction. To 
achieve this aim, the present study was 
intended to measure CXCL5 expression rate 
of patients suffering from NSCLC and 
assess whether it is a suitable biomarker to 
predict the stage of the cancer. 
 
2. Materials and Methods 
2.1 Sampling 
The present study was designed and 
conducted in accordance with the Helsinki 
declaration and relevant guidelines. Ethical 
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approval for this project was obtained from 
ethics committee of Islamic Azad 
University of Tehran with a code of 340/22. 
In this study, 30 patients were selected after 
being diagnosed by the specialist and 
participated in current research after 
completing the informed consent. The 
questionnaire and satisfaction letter was 
prepared as stated in the ethical rules in the 
Experimental Medical Studies of Helsinki. 
The samples were lung tissue biopsies. 
From each patient diagnosed with NSCLC, 
2 biopsies were taken: one from normal 
lung tissue and the other from the tumor (in 
total 60 samples). There were collected 
through bronchoscopy method by the 
specialists from patients admitted to Shahid 
Masih Daneshvari Hospital. These biopsies 
have been gathered regardless of age, 
gender and clinicopathological data. After 
collecting, the tissue samples were 
transferred to the nitrogen tank and were 
preserved in -80°C freezer in accordance 
with principles of transferring and 
maintaining. All ethical guidelines as of 
keeping and using human samples were 
granted. 
 
2.2 Expression Analysis 
     CXCL5 gene expression was measured 
in the patients’ tumor tissue samples and 
their normal lung tissues. Moreover, the 
beta-actin (ACTB) gene was considered as 
the control or reference gene for measuring 
the results. Initially, CXCL5 gene 
expression rate was evaluated in A549 cell 
line; later, the expression level of this gene 
was compared in tumorous and healthy 
tissue samples of patients suffering from 
NSCLC.  
Total RNA extraction was performed from 
both A549 cell line and tissue samples 
(tumor and healthy) by GeneAll kit. After 
RNA extraction, its quality and quantity 
were evaluated through using horizontal gel 
electrophoresis on a 1% agarose gel and 
noanodrop. 
 
To synthesize cDNA, samples with 
absorbance ratio 260/280 mm between 1.8- 
2.0 were applied. 1 µl of RNA was used in 
the Applied Biosystem (ABI). Revert Aid 
First Strand cDNA Synthesise Kit 
(Fermentase) was used to produce cDNA. 
The primers were designed by Primer 
Express software version 3 (Applied 
Biosystems, Austin, TX, USA). The primers 
are presented in Table 1. The sequence of 
ACTB was used as internal control.  
The total reaction components in real-time 
PCR reaction consisted of 12 µl Syber TM 
Master ix, 1 µl forward and reverse primers, 
2µl cDNA and 9 µl sterilized distilled 
water. Real Time PCR was performed for 
CXCL5 and ACTB, using 480 Master mix, 
SYBR Green I (Roche Applied Science) 
with thermal program as follows: initial 
denaturation at 95°C for 4 minutes, the 
second stage over 35 cycles at 95°C for 45 
seconds, 57°C for 30 seconds and 72°C for 
30 seconds. Fluorescence ratio was assessed 
by Exicycler 96 TM. (Bioneer, South 
Korea). Reproduction and separation curves 
were plotted and analyzed by software. In 
order to confirm the amplification of 
components and correctness of PCR 
reaction, the product of Real Time PCR 
reaction was measured by nanodrop device 
and on a 2% agarose gel. The results of 
confirmation on agarose gel are presented in 
Figure 1. Besides, the results of the cycle of 
CXCL5 and ACTB gene expression 
amplifications are plotted in Figure 2.  
Raw data of Real Time PCR was analyzed 
by REST2009 software. All the tests were 
performed in triplicate. The cyclic threshold 
(CT) of CXCL5 and housekeeping gene 
(ACTB) for each sample was determined. 
The ΔCT was calculated by using the CT of 
CXCL5 and ACTB to normalize the data. 
Finally, according to Relative Quantization 
and 2 
-ΔΔCT 
formula, the fold change was 
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Table 1. Nucleotide sequences of primers for CXCL5 and ACTB genes 









Figure 1. Well 1 contains the PCR product of CXCL5 gene, with the length of 126 bp. Well 2 contains the product of 
ACTB gene. The length of the fragment is 88 bp. Well 3 presents the DNA marker. 
 
 
Figure 2. Amplification of ACTB and CXCL5 genes. The vertical axis represents fluorescence amount and the horizontal 
axis shows the number of cycles. The amount of CT for the CXCL5 was 28.4 and for the ACTB was 15.01.  
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2.3 Statistical Analysis 
All statistical analyses were performed 
by SPSS version 20. Pearson's chi-squared 
test and independent t-test were used to 
analyze categorical and continuous 
variables, respectively. P-value < 0.05 was 
considered statistically significant. 
 
3. Results 
     Participants of this study were comprised 
of two groups of lung tissue types (tumor 
and normal), in which 30 individuals were 
included. 18 subjects (60%) were male and 
11 subjects (40%) were female. The mean 
age of patients was 65.4 ± 0.883. Thus, it 
can be argued that age factor has no 
disturbing effect over the studied groups. In 
addition, with a similar comparison made in 
the subgroups of men and women, there is 
still no difference in the average age of 
these subgroups as mentioned previously in 
this study. In the current research, the 
samples were divided into four stages 
according to the state of tumor, which 
included the samples of the first tumor stage 
(6 samples (20%)), second tumor stage (12 
samples (40%)), third tumor stage (5 
samples (16.7%)) and fourth tumor stage (7 
samples (23.3%)).  
The results obtained from real time PCR, 
shown in figure 3 revealed that the relative 
alteration of CXCL5 gene expression in all 
cancerous samples (without considering the 
stage of tumors) was 2.5 fold more than its 
expression in normal samples and their 
difference was statistically significant 
(P<0.05). There was no difference between 
the tumor type (adenocarcinoma, SCC) and 
average CXCL5 gene expression (P = 0.09); 
however, the stage of cancer was 
significantly effective in the change of 
given gene expression (P = 0.03). For 
instance, 5.8-fold increase was detected in 




Figure 3. Relative expression of CXCL5 in different stages of NSCLC. A significant difference (P= 0.03) of CXCL5 
expression in tumors in various stages of NSCLC and normal tissue was identified. For tumor at stage I, II, III and IV the 
measured expression was 1.25±0.1, 2.37±0.23, 3.12±0.08 and 5.85±0.42, respectively. 
 
 In the case of the gender, the expression 
rate of this gene in women was lower than 
men and this difference was statistically 
significant (P = 0.04) (figure 4). The 
significance of this issue is determined 
when it is necessary to measure the 
expression for diagnosis of the disease. 
Consequently, the cut off value specified in 
the diagnosis should be different between 
men and women. This study revealed that 
no relation exists between the expression 
changes of CXCL5 and the age of the 
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patients (P = 0.08). One fascinating finding 
of current study was the difference  
 
ofCXCL5 expression levels between 
smokers and non-smokers (figure 5).  
 
 
Figure 4. Relative expression of CXCL5 in patients of both genders. A significant difference (P= 0.04) has been 
observed. The level of expression in female and male was 2.9±0.66 and 4.8±0.74, respectively.  
 
 
Figure 5. Comparison of CXCL5 relative expression between smokers and non-smokers. In non-smoker patients the 
average of expression was 2.4±0.37; in smokers it was 4.9±0.42.  
 
4. Discussion 
    The results of the current study exhibited 
significant elevation of CXCL5 gene 
expression at 5.8 times in NSCLC biopsies 
compared to normal biopsies of the same 
patients. The results showed a substantial 
link between the degree and severity of 
cancer and increase the expression of 
CXCL5. Therefore, evaluation of this gene 
expression can be suggested as an 
identifying biomarker for NSCLC. 
The results of the present study were 
consistent with the results achieved by Pold 
et al. [16] concerning the increased CXCL5 
expression in cancerous tissues. However, 
in the study carried out by Pold and his 
colleagues, CXCL5 gene expression in 
A549 and H157 lines with cyclooxygenase 
2 was assessed and indeed, the study of this 
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group on CXCL5 expression was more 
comprehensive due to finding a way to treat 
lung cancer through this gene [16]. Their 
results revealed that one of the main reasons 
for the progression of cancer is its ability of 
angiogenesis. As mentioned earlier, CXCL5 
is one of the major angiogenic factors in the 
process of angiogenesis in cancerous tissues 
[17]. Hence, they sought to reduce the 
expression of this gene through inhibiting 
the expression of cyclooxygenase 2 so that 
in this way, they can prevent the 
progression of lung cancer [16] while the 
present study aimed to measure the 
expression of this gene to diagnose the 
disease and establish a relationship its 
expression rate and tumor size. The results 
of current research demonstrated that 
CXCL5 gene expression rate in the 
cancerous tissue and cancerous cell line 
under investigation became 5.8 times higher 
compared to the control group and the 
statistical analysis also showed that this 
difference is quite significant (P<0.05). 
Therefore, it assumed that finding an 
appropriate cut off, it can be used as a 
diagnostic biomarker in disease screening. 
However, other studies have been 
conducted regarding the measurement of 
CXCL5 expression as a factor in the 
diagnosis of cancer, including the research 
of Zhu et al. [18]. In their investigation, the 
measurement of CXCL5 expression was 
used as a factor in the diagnosis of the 
bladder cancer. It was similar to this study 
in that they also used the measurement of 
CXCL5 gene expression in the tissue and 
cell line. The results of their research on the 
cell line indicated that the increased 
expression of the aforementioned gene 
caused increase in the proliferation and 
progression of the tumor cells, and 
expression of this gene in the tissue 
suggests its increased expression relative to 
the normal tissue, which was congruent 
with the results of the present study on the 
lung cancer tissue. Another result obtained 
by this group showed the significant 
relationship between the expression rate and 
cancer stage (P<0.05) [19]. The relationship 
between CXCL5 gene expression and 
disease stage was also evaluated in our 
study and the result of statistical analysis 
revealed that CXCL5 gene expression 
significantly enhances with the disease 
progression (P=0.03) (Figure 2). This 
study's results were consistent with the 
findings achieved by Li et al. [8], in which 
CXCL5 gene expression pattern pancreatic 
cancer was obtained. They demonstrated 
that the expression rate of the mentioned 
gene was raised by the disease progression. 
In addition, the expression rate in men was 
significantly higher than in women (P<0.04) 
[8]. It seems that by the inhibition of 
CXCL5 gene expression, lung cancer can be 
treated. Until now, this issue has been 
proved in some investigations. Miyazaki et 
al. stated that by decreasing the expression 
of this gene through the RNA interference 
technique, the proliferation ability and 
invasion of cancer cells in the culture 
medium can be reduced [19]. Concerning 
the role of chemicals including cigarette in 
the incidence of lung cancer, the role of 
cigarette in increasing CXCL5 gene 
expression was examined in the present 
study and the results suggested that among 
smokers, CXCL5 expression level is almost 
2.5 times higher than that of non-smokers 
(P<0.05) (Figure 3). 
This point has also been proven in other 
studies [20, 21]. In one research, the 
relationship between smoking and the 
function of CXCL5 factors and the 
inflammation was investigated among rats. 
The findings revealed that the rats in which 
CXCL5 gene expression had been inhibited, 
lower response to smoke was observed [22]. 
This could be the approval for the results of 
the present study, indicating the increase of 
CXCL5 expression in smokers. Hence, to 
diagnose cancer in smokers, a higher level 
of CXCL5 gene expression rate should be 
considered as alarming. Since the purpose 
of this study was to use the findings in 
clinical examinations for the diagnosis and 
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treatment of lung cancer, all the factors 
affecting the expression of CXCL5 gene 
should be considered. Another aspect was 
analyzing of the gene expression and the 
tumor type. The expression level was 
compared in adenocarcinoma and SCC and 
it was found that there is no significant 
difference among the types of lung tumors 
in terms of CXCL5 gene expression. 
Accordingly, measurement of this factor 
cannot be helpful in the diagnosis of the 
tumor type. Considering the results obtained 
from this research and similar studies, it can 
be concluded that this factor can be an 
appropriate diagnostic biomarker for the 
early diagnosis of the disease and may be 
used in screening the patients at risk 
through further investigations. In the current 
research, the expression level of CXCL5 
was measured in biopsy samples to 
investigate its amount in normal and 
cancerous biopsies. It should be noted that 
among non-invasive methods, tumor 
biomarkers that are produced in response to 
the presence or progression of cancer from 
the body or tumor tissue and are found 
greatly in blood, urine and tumor tissue 
compared to healthy people are proper 
criteria for the early diagnosis of the disease 
[23]. 
At the end, this project was done 
considering the importance of finding new 
biomarkers to non-invasively diagnose 
NSCLC in people who are at risk. It could 
be better to repeat this investigation on a 
large scale population to achieve more 
precise results and cut offs. For instance, in 
smokers, the results showed there should be 
a higher cut off in comparison to non-
smokers. It is better to consider the disease 
or situation in which people have higher 
level of CXCL5, because this can eliminate 
the probability of errors. Previous  studies 
showed the elevation of CXCL5 protein in 
multiple cancers [9, 24], so evaluation of 
mRNA level of this gene is cost-effective 




     Results obtained from this research and 
similar studies suggest that the CXCL5 
mRNA level in cancerous tissues increases 
drastically. It could be considered as an 
appropriate biomarker for early diagnosis of 
different kinds of NSCLC. As its expression 
is significantly and continuously elevated 
during progression of NSCLC, it can be 
used as a discriminative biomarker to 
categorize various stages of the tumor. In 
addition, it can be a proper tool to screen at-
risk people.  
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